This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in Store for Ironwood (IRWD) This Earnings Season?
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.
Options Traders Expect Huge Moves in Karyopharm (KPTI) Stock
by Zacks Equity Research
Investors need to pay close attention to Karyopharm (KPTI) stock based on the movements in the options market lately.
BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU
by Zacks Equity Research
The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.
Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I
by Zacks Equity Research
Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.
Top Ranked Momentum Stocks to Buy for January 13th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 13th
Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics
5 Stocks With Recent Price Strength for Spectacular Returns
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Are You Looking for a Top Momentum Pick? Why Karyopharm Therapeutics (KPTI) is a Great Choice
by Zacks Equity Research
Does Karyopharm Therapeutics (KPTI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4%
by Zacks Equity Research
Karyopharm (KPTI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 20.24% and 718.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Signs $150M Royalty Agreement to Support Xpovio
by Zacks Equity Research
Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.
Bristol-Myers' (BMY) Opdivo Falls Flat in Brain Tumor Study
by Zacks Equity Research
Bristol-Myers (BMY) announces dismal results from a late-stage study on its immuno-oncology drug Opdivo for critical brain tumor.
Earnings Preview: Karyopharm Therapeutics (KPTI) Q2 Earnings Expected to Decline
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Karyopharm Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Karyopharm Therapeutics.
Karyopharm Gets Accelerated FDA Approval for Myeloma Drug
by Zacks Equity Research
Karyopharm (KPTI) gets accelerated FDA approval for oral Xpovio in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.
Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -29.76% and -79.39%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Karyopharm Therapeutics (KPTI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Karyopharm Stock Up Even as FDA Delays Selinexor NDA Verdict
by Zacks Equity Research
Karyopharm's (KPTI) stock rises despite the FDA's decision to delay the verdict on the NDA filing of selinexor, which is developed for treating patients with relapsed-refractory multiple myeloma.
Karyopharm Files MAA for Myeloma Candidate Selinexor in EU
by Zacks Equity Research
Karyopharm (KPTI) tenders a marketing application to European regulatory authority with the purpose of seeking an approval for selinexor to address patients with penta-refractory multiple myeloma.
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 10.23% and -80.25%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 21.05% and 233.07%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Initiates NDA Submission Process for Selinexor
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) initiates rolling submission of a New Drug Application to the FDA with a request for accelerated approval for selinexor.
Is the Options Market Predicting a Spike in Karyopharm Therapeutics (KPTI) Stock?
by Zacks Equity Research
Surgiing implied volatility makes Karyopharm Therapeutics (KPTI) stock lucrative to the option traders.
Karyopharm's Myeloma Candidate Gets Fast Track Designation
by Zacks Equity Research
The FDA grants a fast track status to Karyopharm's (KPTI) selinexor for treatment of multiple myeloma. Selinexor is also evaluated in several mid- and later-phase studies on multiple cancer indications.